GlobeNewswire
-
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit
06/01/2026 -
Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
06/01/2026 -
FibroBiologics to Present at 9th Annual BFC Global Healthcare Business Development and Investment Conference
06/01/2026 -
LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.
06/01/2026 -
Milestone Scientific Launches The Wand® Ambassador Program to Expand Peer Engagement and Accelerate Market Adoption in Dentistry
06/01/2026 -
Vericel to Present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026
06/01/2026 -
CVRx Announces Implementation of New Category I CPT Codes for Barostim Therapy
06/01/2026 -
SS Innovations Develops New Instruments to Advance Robotic Surgery in Large, Underserved Patient Segments, including Pediatric and Cardiac Markets
06/01/2026 -
Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared
06/01/2026 -
Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer
06/01/2026 -
VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer
06/01/2026 -
24/7 Market News- Kraig Labs Breakthrough Science is Pivoting to Scalable Business
06/01/2026 -
GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N
06/01/2026 -
GENFIT : Profil de sécurité favorable en Phase 1 et forte activité anti-inflammatoire pour G1090N, actif clé dans l’ACLF
06/01/2026 -
Clinical Neurology Specialists Partnering with Leading International Nonprofit to Accelerate Alzheimer’s Research in Las Vegas
06/01/2026 -
Ipsen – Half year statement – 2025 12 31
06/01/2026 -
Ipsen - Bilan semestriel - 31 12 2025
06/01/2026 -
Transparency Notification from Shareholders
06/01/2026 -
A Race Against Blindness Awards Additional $1.1 Million Grant to Ensure Advancement of AXV-101 into Clinical Trial for Bardet-Biedl Syndrome 1 (BBS1)
06/01/2026
Pages